SWOG clinical trial number
CTSU/R0524

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer

Closed
Phase
Abbreviated Title
Muscle-Invasive Bladder Ca, Paclitaxel, Trastuzumab, RT vs Paclitaxel, RT, Ph III
Activated
12/15/2006
Closed
02/22/2013
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Paclitaxel Trastuzumab Radiation Therapy

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2014

The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer

MD Michaelson;C Hu;HT Pham;MD Dahl;CL Wu;RM Whittington;G Swanson;J Vuky;RJ Lee;L Souhami;BK Chang;A George;HM Sandler;WU Shipley Journal of Clinical Oncology 32(suppl 4; abstr LBA287), oral; ASCO GU Cancers Symposium

Other Clinical Trials

SWOG Clinical Trial Number
S2312
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200